FDA's Avastin Decision Puts Pressure On Progression-Free Survival Endpoints
Executive Summary
As FDA started to reconsider the approval of Roche/Genentech's Avastin for metastatic breast cancer, many were concerned about the decision's potential implications for other applications using progression-free survival as an endpoint.
You may also be interested in...
Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early
Pfizer’s development of Sutent (sunitinib) for treatment of pancreatic tumors shows the potential pitfalls sponsors face when they decide to terminate clinical trials early due to positive results.
Sutent Pancreatic Tumor Study Shows Regulatory Pitfalls Of Stopping Early
Pfizer’s development of Sutent (sunitinib) for treatment of pancreatic tumors shows the potential pitfalls sponsors face when they decide to terminate clinical trials early due to positive results.
Early Study Termination Is Key Issue In ODAC Review Of Pfizer's Sutent For Pancreatic Cancer
FDA is asking its Oncologic Drugs Advisory Committee whether sunitinib's risk/benefit profile in pancreatic neuroendocrine tumors is favorable given that early termination of the Phase III trial created uncertainty about the magnitude of its progression-free survival benefit.